Kezar Life Sciences, Inc. (KZR) Depreciation & Amortization (CF) (2017 - 2026)

Kezar Life Sciences has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $47000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 81.27% year-over-year to $47000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $693000.0 (down 32.78% YoY) and the FY2025 annual result came in at $897000.0, down 13.75% from the prior year.
• Depreciation & Amortization (CF) slipped to $47000.0 in Q1 2026 per KZR's latest filing, from $176000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $458000.0 in Q3 2022 and troughed at -$283000.0 in Q4 2022.
• A 5-year average of $239588.2 and a median of $259000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) plunged 173.13% in 2022, then jumped 198.94% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at -$283000.0 in 2022, then surged by 198.94% to $280000.0 in 2023, then declined by 7.5% to $259000.0 in 2024, then plunged by 32.05% to $176000.0 in 2025, then sank by 73.3% to $47000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $47000.0, $176000.0, and $227000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.